It has not been firmly established whether disturbed calcium-phosphate metabolism affects
progression of chronic kidney disease (CKD) in humans. In this cohort study of 227
nondiabetic patients with CKD, we assessed fibroblast growth factor 23 (FGF23) plasma
concentrations in addition to other variables involved in calcium-phosphate metabolism, and
we followed 177 of the patients prospectively for a median of 53 months to assess
progression of renal disease. In the baseline cohort, we found a significant inverse …